Humanwell Healthcare (SHA:600079) subsidiary Yichang Humanwell Pharmaceutical received clinical trial approval from China's National Medical Products Administration for its RFUS-949 tablets for postoperative pain.
The trial will evaluate the efficacy and safety of the tablets for pain relief after abdominal surgery, according to a Friday filing with the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.